最新公告列表 《关于诉讼事项的进展公告（三）》 截至2026年1月23日收盘，创新医疗（002173）报收于29.88元，较前一交易日上涨3.28%，最新总市值 为131.86亿元。该股当日开盘30.0元，最高30.45元，最低28.75元，成交额达23.03亿元，换手率为 18.59%。 近日，创新医疗管理股份有限公司披露《关于诉讼事项的进展公告（三）》。公告显示，公司于近日收 到上海金融法院就韩猛起诉公司及公司时任董事一案作出的终审判决，案号为（2025）沪74民终1586 号。法院判决驳回上诉，维持原判。二审案件受理费193,877元，由韩猛负担9,672元，公司负担184,205 元。该判决为终审判决。公司表示，本案对公司本期利润或期后利润无重大影响。截至公告日，公司及 控股子公司不存在应披露而未披露的其他重大诉讼、仲裁事项。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Core Viewpoint - The article discusses the volatility and potential of AI application stocks, highlighting the recent surge and subsequent decline in their prices, emphasizing the need for logical investment rather than speculative trading [3][4][6]. Group 1: AI Application Market Dynamics - The AI application market saw a significant surge starting January 9, driven by the IPO of MiniMax, which rose over 90%, boosting market confidence in AI commercialization [3][4]. - Following the initial excitement, many AI companies issued announcements clarifying their limited revenue from AI, leading to a sharp price correction in the sector [4][5]. - The article suggests that while the current market may present opportunities, investors should focus on companies with genuine value and sustainable business models [4][7]. Group 2: GEO Model in Advertising - The article introduces the GEO (Generative Engine Optimization) model as a transformative approach in advertising, allowing users to input specific demands and receive optimized product recommendations directly from AI [9][11]. - The GEO market is projected to grow significantly, with estimates of $2.9 billion in China and $11.2 billion globally by 2025, indicating a shift from traditional SEO to AI-driven marketing strategies [11][12]. - Companies that own AI models and user behavior data are expected to be the primary beneficiaries of the GEO model, similar to how Google and Baidu benefited during the SEO era [12][13]. Group 3: AI in Healthcare - The AI healthcare sector has shown strong performance, with companies like 泓博医药 and 迪安诊断 seeing over 50% gains year-to-date, driven by increasing market interest [22][24]. - Government policies are increasingly supportive of AI in healthcare, with initiatives aimed at integrating AI into medical services and diagnostics [24][25]. - The article notes that advancements in AI healthcare applications, such as OpenAI's ChatGPT Health, are enhancing market sentiment and could lead to further growth in the sector [26][29]. Group 4: AI in Financial Technology - The financial technology sector has also experienced growth, with a 14% increase in the financial technology ETF as of January 14, 2026 [37]. - AI is expected to enhance the capabilities of both internet finance companies and financial IT firms, improving customer engagement and operational efficiency [38][39]. - However, the article cautions that while AI can improve operational efficiencies, it may not fundamentally change the poor business models prevalent in financial IT companies [40].

Core Viewpoint - The medical services sector experienced a rise of 1.19% on January 23, with notable gains from companies like Nuohua Zhiyuan, which led the sector's performance [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4136.16, up 0.33%, while the Shenzhen Component Index closed at 14439.66, up 0.79% [1]. - The medical services sector saw significant individual stock movements, with Nuohua Zhiyuan (688315) closing at 17.00, up 13.26%, and Hai Te Biological (300683) closing at 33.31, up 7.66% [1]. Group 2: Trading Volume and Value - Nuohua Zhiyuan had a trading volume of 219,500 shares and a transaction value of 365 million yuan [1]. - Hai Te Biological recorded a trading volume of 190,900 shares with a transaction value of 632 million yuan [1]. Group 3: Capital Flow - The medical services sector saw a net inflow of 999.1 million yuan from institutional investors, while retail investors experienced a net outflow of 1.069 billion yuan [2]. - The capital flow data indicates that major stocks like Diyan Diagnosis (300244) had a net inflow of 288 million yuan from institutional investors [3].

证券代码：002173 证券简称：创新医疗 公告编号：2026-004 驳回上诉，维持原判。 二审案件受理费 193,877 元，由上诉人韩猛负担 9,672 元，上诉人创新医疗 管理股份有限公司负担 184,205 元。 本判决为终审判决。 二、上述案件对公司本期利润或期后利润的可能影响 创新医疗管理股份有限公司 关于诉讼事项的进展公告（三） 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 2025年9月，上海市浦东新区人民法院对韩猛以公司未办理相关股份的解除 限售手续为由，起诉公司及公司时任董事的相关案件作出一审判决。其后，公司 和韩猛均不服上述一审判决，向上海金融法院提起上诉，具体情况详见2025年11 月28日公司披露于《证券时报》、《证券日报》、《中国证券报》、《上海证券 报》以及巨潮资讯网(http://www.cninfo.com.cn)的相关公告（公告编号： 2025-054）。近日，公司收到上海金融法院关于上述案件的《民事判决书》（（2025） 沪74民终1586号）。现将有关情况公告如下： 一、本次收到《民事判决书》判决情况 公司于近日收到 ...

Market Overview - The medical services sector experienced a decline of 0.25% on January 22, with Chengda Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 4122.58, up 0.14%, while the Shenzhen Component Index closed at 14327.05, up 0.5% [1] Stock Performance - Notable gainers in the medical services sector included: - Yinos (688710) with a closing price of 66.35, up 5.96% [1] - Hite Bio (300683) at 30.94, up 4.28% [1] - Puri Eye (301239) at 34.79, up 3.73% [1] - Conversely, significant decliners included: - Chengda Pharmaceutical (301201) at 39.67, down 4.16% [2] - Nanmo Bio (688265) at 48.21, down 3.17% [2] - Pruis (301257) at 66.99, down 2.63% [2] Capital Flow - The medical services sector saw a net outflow of 313 million yuan from institutional investors, while retail investors experienced a net inflow of 89.45 million yuan [2] - The capital flow for specific stocks showed: - Innovation Medical (002173) had a net inflow of 89.74 million yuan from institutional investors [3] - Kanglong Chemical (300759) saw a net inflow of 44.95 million yuan from institutional investors [3] - Chengda Pharmaceutical (301201) had a net outflow of 20.46 million yuan from retail investors [3]

据东北证券研报，精锋医疗为国产手术机器人前二强，多孔腔镜、单孔腔镜、自然腔道机器人海内外快 速放量，2025年国内腔镜机器人招采中标数位居国产第一。远程术式2025年11月获NMPA批准，2025年 10月实现500例手术里程碑。 精锋医疗-B(02675)再涨超7%，昨日大涨超11%。截至发稿，涨7.34%，报70.95港元，成交额4818.49万 港元。 消息面上，近日，国家医保局发布《手术与治疗辅助操作类医疗服务价格项目立项指南(试行)》，为手 术机器人、能量设备专用耗材及远程手术等创新医疗（002173）技术明确了全国统一的价格立项规范。 中邮证券认为，国家统一机器人手术收费框架，将成手术机器人行业商业化重要转折事件。 ...

Core Insights - The article discusses Shenzhen's new action plan aimed at leveraging the insurance industry to support technological innovation and industrial development from 2026 to 2028 [1][11]. Group 1: Action Plan Overview - The action plan outlines sixteen measures to enhance insurance support for technology innovation and industrial development, with specific responsibilities assigned to various units [3][4]. - The plan aims to establish a modern insurance service system aligned with Shenzhen's economic development, supporting strategic emerging industries and enhancing financial cooperation with Hong Kong [4][12]. Group 2: Goals and Targets - By the end of 2028, the plan targets an annual risk coverage of over 5 trillion yuan for technology enterprises, with an average annual growth rate of over 10% in technology insurance premium income [4][12]. - The total assets of insurance entities in Shenzhen are expected to exceed 11 trillion yuan, with total premium income surpassing 700 billion yuan over three years [5][13]. Group 3: Specific Measures - The plan includes optimizing insurance fund utilization, promoting technology insurance, and enhancing support for the "20+8" strategic emerging industry clusters [6][14]. - It encourages insurance institutions to invest over 1 trillion yuan in Shenzhen, focusing on key sectors such as artificial intelligence, biotechnology, and low-altitude economy [6][7]. Group 4: Collaboration and Innovation - The action plan emphasizes collaboration between the insurance industry and various sectors, including the establishment of insurance innovation centers and the development of tailored insurance products for emerging technologies [8][15]. - It also highlights the importance of enhancing the insurance service system for the marine industry and promoting cross-border insurance cooperation with Hong Kong [17][19]. Group 5: Support and Coordination - The plan outlines measures to strengthen organizational coordination and promote public awareness of insurance policies and products [21][22]. - It aims to facilitate the integration of insurance services with industrial needs, enhancing the efficiency and effectiveness of insurance offerings [21][22].

剩余财产分配完毕后，本基金管理人将按照法律法规及相关规定办理本基金的账户注销等业务。投资人 可拨打本基金管理人的客户服务电话（400-700-8880）了解相关事宜。 华商基金管理有限公司 本基金自2025年12月20日至2025年12月29日期间进行了基金财产清算，基金财产清算报告报中国证监会 备案后，本基金管理人于2026年1月20日在本基金管理人网站（www.hsfund.com）和中国证监会基金电 子披露网站（http://eid.csrc.gov.cn/fund）刊登了《华商创新医疗混合型证券投资基金清算报告》（以下 简称"《清算报告》"）。根据《基金合同》的约定，《基金合同》终止日是指《基金合同》规定的《基 金合同》终止事由出现后，基金财产清算完毕，清算结果报中国证监会备案并予以公告的日期。据此， 本基金《基金合同》终止日为2026年1月20日。 根据《中华人民共和国证券投资基金法》《公开募集证券投资基金运作管理办法》《华商创新医疗混合 型证券投资基金基金合同（更新）》（以下简称"《基金合同》"）的有关规定，华商创新医疗混合型证 券投资基金（以下简称"本基金"）已出现触发《基金合同》终止的情形，华 ...

Core Insights - The National Healthcare Security Administration (NHSA) has officially issued the "Guidelines for the Pricing Project of Surgical and Treatment Auxiliary Medical Services (Trial)" which standardizes pricing for 37 projects, 5 additional charges, and 1 expansion item related to medical technology innovations such as 3D printing and robotic surgery [1][2] Group 1: Industry Overview - The domestic surgical robot industry has started late and has been dominated by foreign brands, but the release of the pricing guidelines and the continuation of policies favoring large-scale equipment updates are expected to accelerate the penetration rate of surgical robots [1] - The market for domestic surgical robots is showing strong potential for replacement, particularly in second and third-tier hospitals, as local brands demonstrate significant cost-performance advantages [1] Group 2: Market Dynamics - The monopoly of the Da Vinci surgical robot is gradually being reshaped, with domestic brands like Weigao, Jisheng, Sizhirui, and Shurui increasing their market share, indicating a shift from a "monopoly" to "multi-strong competition" in the laparoscopic surgical robot market [1] - According to RoboticTech, by 2025, domestic brands are expected to surpass imported brands in terms of bidding volume for laparoscopic surgical robots, further compressing Da Vinci's market share [1] Group 3: Investment Opportunities - CITIC Securities suggests that investors should focus on the surgical robot industry and its upstream and downstream supply chains, as well as high-value consumables in fields such as minimally invasive surgery, orthopedics, gastroenterology, cardiovascular, and neurology [3] - The NHSA's new policy is expected to accelerate the promotion and popularization of surgical robots in China, benefiting the overall innovative medical device sector [2] Group 4: Company Highlights - Precision Medical (02675) is recognized as a leading domestic surgical robot company, being the first in China and the second globally to obtain regulatory approval for multiple types of laparoscopic surgical robots [4] - MicroPort (02252) has reported a cumulative order of over 230 surgical robots, with more than 160 being laparoscopic surgical robots, indicating strong market validation of its global strategy [4] - Kangji Medical (09997) is a leading company in minimally invasive surgical consumables, strategically investing in Weijing Medical to expand its product offerings, with expectations of significant growth as domestic surgical robots become more prevalent [5]

Group 1 - The National Healthcare Security Administration (NHSA) issued the "Guidelines for the Pricing Project of Surgical and Treatment Auxiliary Medical Services (Trial)" to standardize pricing for innovative medical technologies, including 3D printing and robotic surgery, establishing 37 pricing items and additional charges [1][2] - The guidelines aim to create a unified pricing framework for surgical robots and remote surgeries, allowing innovative products to achieve reasonable premiums and promoting the flow of quality medical resources [1][2] - The guidelines introduce a new pricing project for remote surgical assistance, enabling experts in resource-rich areas to provide remote surgeries to patients in other regions, thus reducing the burden of travel for patients [2] Group 2 - The NHSA plans to complete the compilation of the guidelines to achieve a basic unification of medical service pricing projects nationwide, improving the quality and efficiency of the review process for new pricing projects [2] - The pricing framework for surgical robots will be based on their level of participation in surgeries, with higher fees for robots that are more involved and precise, while also considering cost-sharing and patient accessibility [2][3] - The establishment of a national unified pricing for surgical robots is expected to promote the widespread application of robotic surgery technology, enhancing the commercialization process of innovative medical equipment [3][4] Group 3 - The guidelines are anticipated to encourage domestic R&D enterprises, shorten the promotion cycle of new technologies, and drive down costs in the domestic supply chain [4] - The focus on the clinical value of robotic surgery is expected to guide and incentivize companies to develop high-value technologies that can participate more deeply in core surgical procedures [3] - The guidelines will help resolve clinical translation issues for innovative technologies like precision navigation and surgical robots, benefiting patients and promoting high-quality development in the medical equipment industry [3]